Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.6 USD | +0.19% | -0.59% | +4.27% |
May. 13 | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
May. 09 | Medincell: share price rises on resumption of trading | CF |
ETFs positioned on AbbVie Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.72% | 57 M€ | +21.13% | - | |
0.72% | 36 M€ | +22.19% | ||
0.71% | 2,517 M€ | +12.14% | - | |
0.69% | 22 M€ | +14.86% | ||
0.69% | 1 M€ | -.--% | ||
0.67% | 8 M€ | +5.48% | - | |
0.66% | 7 M€ | +6.22% | - | |
0.65% | 34 M€ | +11.62% | - | |
0.62% | 414 M€ | +11.73% | - | |
0.62% | 1,006 M€ | -.--% | - | |
0.57% | 283 M€ | +20.21% | ||
0.57% | 322 M€ | +13.88% | - | |
0.57% | 29 M€ | -.--% | - | |
0.53% | 14 M€ | +16.19% | - | |
0.53% | 1 M€ | +3.03% | - | |
0.48% | 5 M€ | -.--% | - | |
0.46% | 1,166 M€ | +0.26% | - | |
0.46% | 607 M€ | +0.05% | - | |
0.46% | 571 M€ | +7.35% | - | |
0.45% | 284 M€ | -.--% | ||
0.45% | 727 M€ | +8.46% | ||
0.45% | 37 M€ | -.--% | ||
0.45% | 786 M€ | -.--% | ||
0.45% | 23 M€ | -.--% | - | |
0.44% | 0 M€ | 0.00% | - | |
0.42% | 206 M€ | -.--% | ||
0.41% | 9 M€ | +9.94% | - | |
0.41% | 391 M€ | +8.36% | - | |
0.39% | 34 M€ | +8.28% | - | |
0.37% | 25 M€ | +4.02% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 285B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B | |
-1.42% | 161B |
- Stock Market
- Equities
- ABBV Stock
- Funds and ETFs AbbVie Inc.